Evidence map›Paper›PMID 42059613›Full record

ArticleApplied and environmental microbiology2026

Sai Simha Reddy Vakamalla, David A Sack, Weiping Zhang

Abstract read
In one paragraph

Article in Applied and environmental microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sai Simha Reddy VakamallaDepartment of Pathobiology, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.ORCID 0000-0003-1048-6377
David A SackDepartment of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-9338-5119
Weiping ZhangDepartment of Pathobiology, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.ORCID 0000-0002-3723-2257

Funding

Development of MecVax, a Cross Protective Subunit Vaccine for ETECR01AI177144 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI WEIPING ZHANG · 2023 to 2026
$4.6M
A cross protective multivalent vaccine for Shigella and ETECR01AI175214 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DAVID A SACK · 2023 to 2026
$3.0M
NIH HHS R01AI175214NIH HHS R01AI177144
6 · The paper itself

Abstract

The persistent and deadly cholera remains a significant burden on global health. Current countermeasures are inadequate against cholera. Toxin-coregulated pilin (TCP) has long been a target for understanding the biogenesis of

Indexed as

Antibodies, BacterialBacterial AdhesionCholeraCross ProtectionEpitopesEpitopes, B-LymphocyteFimbriae ProteinsVibrio cholerae O1AnimalsCholera VaccinesMiceProtein Subunit VaccinesAntibodies, BacterialCholera VaccinesEpitopesEpitopes, B-LymphocyteFimbriae ProteinsProtein Subunit VaccinesTcpA protein, Vibrio choleraebiogenesisbiotype-specific immunitycholeraepitopeTcpAvaccineVibrio cholerae

Identifiers

PMID42059613
PMCPMC13188898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.